regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant cholesterol-lowering benefits on top of weight loss—a differentiation strategy aimed at competing with Eli Lilly's and Novo Weight-Loss Drugs: How Outliers Like

Ex9 had no effect on glucose tolerance in linagliptin-treated GcgRANull or in GcgRAVilCre mice

Redistribution or transfer prohibited

Discover what to expect, how long symptoms last, and proven strategies to manage them during your journey.

These easy-to-use patches are perfect for anyone seeking a portable, lightweight solution that fits seamlessly into a busy lifestyle

GLP-1 side effects explained for Indian patients: nausea, muscle loss, hair loss, Ozempic face, and who should avoid Wegovy, Mounjaro, or Ozempic.

Adults with type 2 diabetes assigned an SGLT2 inhibitor or a GLP-1 receptor agonist during cardiovascular outcomes trials derived benefit from the therapies regardless of whether they were prescribed insulin, according to a meta-analysis.In an analysis of data across eight large, multiyear CV outcomes trials for three classes of diabetes agents, researchers also found that participants using